Prof Tobias Maurer speaks to ecancer about the results from the phase 3 LIGHTHOUSE study. The LIGHTHOUSE study evaluated 18F-rhPSMA-7.3’s diagnostic performance in men with newly diagnosed unfavourable intermediate to very high-risk prostate cancer who were scheduled for radical prostatectomy and pelvic lymph node dissection.
The study found that 18F-rhPSMA-7.3 PET provides high specificity and clinically useful information regarding the presence of N1 disease prior to surgery in this specific patient population.
Prof Maurer says that the trend of lower sensitivity is consistent within the class of PSMA-PET ligands.
He concludes by discussing the clinical impact of these results.